AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 152 min read$FICO

Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA)

Analysts updated ratings for NA sector companies. Clear Street's Owen Lau reiterated a Buy rating on Fair Isaac (FICO) with a $1600 price target. Freeport-McMoRan (FCX) was kept at Hold by Bernstein's Bob Brackett. BioAge Labs (BIOA) received a Buy rating from Needham's Joseph Stringer with a $35 target. Analyst consensus for FICO is Moderate Buy, FCX is Strong Buy, and BIOA is Strong Buy.

Original reporting
theglobeandmail.com
Published Sep 15, 2026, 11:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$FICOBullishMed
01

Why it matters

While the analyst opinions are fresh, they lack accompanying earnings or operational news, limiting immediate market impact.

02

Market read

Analyst rating updates may influence short-term trading decisions but are unlikely to drive major price moves without additional catalysts.

03

What to watch

No new fundamental data accompanies the rating changes; macro factors could dominate price action.

Relevance 5/10Novelty 5/10Timing: today

Background

The article aggregates analyst rating updates for three North American companies, providing new price targets and consensus views.

Company-level read

Ticker impact

$FICOBullishMedium confidence
Context

Clear Street analyst Owen Lau reiterated a Buy rating and raised the price target to $1,600, providing a fresh bullish outlook.

Expected impact

Potential modest price appreciation if investors follow the new target.

Evidence & confidence

The rating change is new and includes a sizable target increase, but no fundamental catalyst accompanies it.

$FCXNeutralLow confidence
Context

Bernstein analyst Bob Brackett maintained a Hold rating on Freeport-McMoRan, confirming the existing consensus.

Expected impact

Little to no immediate price movement expected.

Evidence & confidence

The rating unchanged and no new target shift reduces actionable significance.

$BIOABullishMedium confidence
Context

Needham analyst Joseph Stringer maintained a Buy rating and set a $35 price target, reinforcing a strong upside thesis.

Expected impact

Possible upside if investors price in the new target.

Evidence & confidence

The rating is unchanged but the high target highlights growth expectations.

Market effects

Sector

Analyst upgrades may lift sentiment in the financial services and biotech sectors.

Regional

North American markets could see modest buying pressure in the highlighted stocks.

Global

Limited; impact confined to U.S.-listed issuers.

Counterpoint

What could challenge this read

Ratings reaffirmations may be already priced in; investors should await concrete earnings or product news.

Key entities

  • Analyst Firm
    Clear Street

    Provided a Buy rating and $1,600 target for FICO.

  • Analyst Firm
    Bernstein

    Maintained a Hold rating for FCX.

  • Analyst Firm
    Needham

    Maintained a Buy rating and $35 target for BIOA.

Read at source← All news

Related articles

SEP 16
$FCXMed

Freeport-McMoRan Eyes Leach Breakthrough, Bagdad Growth and Grasberg Recovery

Freeport-McMoRan (FCX) is testing new technologies to boost copper production from stockpiles, aiming to increase annual leach output to 800M pounds over 3-4 years. The company is also evaluating an expansion at its Bagdad mine in Arizona, pending a board review. In Indonesia, Grasberg mine is recovering from a mud rush incident and expects full capacity by late 2027. FCX is also operating two smelters in Indonesia. U.S. copper tariffs remain uncertain, and the company plans to allocate half of

finance.yahoo.com3 min
SEP 15
$FCXMedAI 8/10

Will FCX's Margins Hold Up as Copper Production Costs Rise?

Freeport-McMoRan (FCX) reported higher Q2 earnings due to increased metal prices, but faces rising production costs. Q2 unit net cash costs rose 74% YoY to $1.97 per pound, with Q3 expected at $2. Copper sales volumes fell 30% YoY to 710M pounds. FCX projects full-year average costs of $1.9 per pound, up from $1.65 in 2025. Peers like Southern Copper (SCCO) and BHP (BHP) reported mixed cost trends.

tradingview.com2 min
SEP 15
$FCXMed

Freeport-McMoRan Stock Drops Nearly 8% as Copper’s Record Rally Hits a Wall

Freeport-McMoRan's stock dropped nearly 8% to $70.43 after a Reuters report indicated uncertainty around U.S. copper import tariffs. The decline followed a record copper rally, with futures reaching $6.89 per pound. Analysts note the rally may have outpaced fundamentals, and the company faces operational challenges. Other copper producers and ETFs also saw declines.

abcmoney.co.uk1 min
SEP 13
$FICOLow

UBS Remains a Hold on Fair Isaac (FICO)

UBS analyst Kevin Mcveigh kept a Hold rating on Fair Isaac (FICO) with a $1,100 target. Shares closed at $985.39. The consensus is Moderate Buy with a $1,515.82 target. FICO reported Q2 revenue of $674.19M and net profit of $237.17M, up from last year. Insider sentiment is negative, with recent sales by directors.

theglobeandmail.com2 min